Printer Friendly

PHARMOS RESEARCHERS PRESENT DATA ON HU-211 AS A NEUROPROTECTANT IN STROKE AND HEAD TRAUMA

 NEW YORK, July 14 /PRNewswire/ -- Pharmos Corporation (NASDAQ Small Cap: PARS) reported today that data will be presented on its neuroprotective agent HU-211, showing its activity in attenuating brain injury relating to both stroke and head trauma. At the "Recent Advances in the Diagnosis, Prevention and Treatment of Ischemic Stroke" meeting which runs July 14-15, in Philadelphia, Pharmos researcher Anat Biegon, Ph.D., will present data showing the ability of HU-211 to protect neurons from ischemic or exitotoxic damage both in vivo and in culture. The results being presented show that gerbils subjected to global forebrain ischemia via common carotid occlusion, followed by treatment with HU-211, experienced a reduced number and severity of neurological symptoms and a significantly higher number of surviving neurons in the hippocampal CA1 field than untreated gerbils. Studies on HU-211 activity in culture will also be presented at the meeting.
 In addition, a journal article on the cerebroprotective effects of HU-211 in head trauma will be published in an upcoming issue of "The Journal Neurotrauma." In this paper, E. Shohami, Ph.D. et. al., describes the cerebroprotective effects of the compound in a model of closed head injury in rats. The clinical status of the rats was evaluated one, 24 and 48 hours after injury, and the extent of edema formation was determined by specific gravity and water content measurements. The drug was found to be very effective in improving motor function recovery reducing blood brain barrier breakdown by more than four times controls, and reducing cerebral edema. The drug was effective in reducing the pathological symptoms even if given three hours after trauma.
 Pharmos Corporation is engaged in the development of novel pharmaceuticals based on innovative drug delivery technologies targeting diseases of the eye, principally glaucoma and ocular inflammation, and the brain, principally stoke and head trauma.
 -0- 7/14/93
 /CONTACT: Stephen R. Streber, president and COO of Pharmos Corporation, 212-838-0087; or Anthony J. Russo of Noonan/Russo Communications, 212-979-9180, or Donald O. Weinberger of Strategic Growth International, 212-826-9622, both for Pharmos/
 (PARS)


CO: Pharmos Corporation ST: New York IN: MTC SU:

CK-LR -- NY028 -- 1303 07/14/93 10:34 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 14, 1993
Words:357
Previous Article:ZIONS FIRST NATIONAL BANK RECEIVES OCC APPROVAL TO PROCEED WITH DISCOUNT CORP. TRANSACTION
Next Article:MISSOURI $285.4 MILLION GENERAL OBLIGATION BONDS AND GENERAL OBLIGATION REFUNDING BONDS RATED 'AAA' BY FITCH -- FITCH FINANCIAL WIRE --
Topics:


Related Articles
PHARMOS RESEARCHERS PRESENT DATA ON THE THERAPEUTIC VALUE OF HU-211, A NEUROPROTECTANT IN HEAD TRAUMA AND STROKE
PHARMOS ANNOUNCES THE SUCCESSFUL COMPLETION OF PHASE III CLINICAL TRIALS FOR LOTEMAX
PHARMOS ANNOUNCES SUBMISSION OF CHEMISTRY, MANUFACTURING AND CONTROL SECTION OF LOTEMAX NEW DRUG APPLICATION (NDA) TO FDA
PHARMOS ANNOUNCES SUBMISSION OF CHEMISTRY, MANUFACTURING AND CONTROL SECTION OF LOTEMAX NEW DRUG APPLICATION (NDA) TO FDA
PHARMOS SUBMITTED LOTEMAX CLINICAL PACKAGE TO FDA ADDRESSING $500 MILLION MARKET
PHARMOS PRESENTS LOTEMAX CLINICAL RESULTS AT ARVO CONVENTION
PHASE I CLINICAL TRIAL COMPLETED ON DEXANABINOL - A POTENTIAL NEUROPROTECTING DRUG TO TREAT STROKE
PHARMOS ANNOUNCES COMPLETION OF PHASE III STUDIES FOR NEW PRODUCT TO TREAT ALLERGIES OF THE EYE
Pharmos Corporation Product Development Update
Pharmos Announces Successful Phase II Head Trauma Study; Marijuana Analog Benefits Brain Injured Patients.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters